Telomir-1 Lowers PSA Levels and Reduces Tumor Volume in Prostate Cancer Studies
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals Inc. announced preclinical data showing Telomir-1 reduces PSA levels and tumor volume in prostate cancer studies. Telomir-1 lowers PSA in a dose-dependent manner and reduces cellular energy metabolism and viability. In mouse models, it reduced tumor volume alone and with paclitaxel, without treatment-related mortality. The company is preparing for an IND submission. The announcement was made via EDGAR by Telomir Pharmaceuticals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments